VANCOUVER, Aug. 7 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that the results of a study using the Company's platform Photodisinfection technology to eliminate Pseudomonas aeruginosa will be published in the peer-reviewed journal Photochemistry and Photobiology.
The article has been e-published ahead of the print version and is currently available online at http://www3.interscience.wiley.com/journal/120121002/issue.
P. aeruginosa is an opportunistic pathogen renowned for its ability to live in practically any environment, including distilled water or even some hospital disinfectant solutions. It is notorious for being resistant to almost all antibiotics, and it is often the source of intractable infections in cystic fibrosis patients where the fatality rate can approach 50%. In the recently published article entitled, "In Vitro Photodynamic Eradication of Pseudomonas aeruginosa in Planktonic and Biofilm Culture", Ondine researchers conclusively demonstrated rapid eradication of P. aeruginosa in both free-floating (planktonic) and the highly-resistant biofilm forms.
"We believe that Ondine's platform photodisinfection technology can
scale to address numerous clinically unmet needs," stated Dr. Cale Street,
Ondine's Director of Research. "Pseudomonads can cause dangerous infections
in humans including respiratory infections, burn and wound infections,
bacteremias, severe external ear infections, and bone and joint infections.
Pseudomonads are one of the most difficult-to-kill microorganisms. Our
photodisinfection technology has proven capable of eradicating this
virulent pathogen in short time periods, without producing dangerous
by-products. In addition, Photodisinfection does not induce the bacterial
resistance factors that compromi
|SOURCE Ondine Biopharma Corporation|
Copyright©2008 PR Newswire.
All rights reserved